Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 16/20 | 0.74 |
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | XDH | P47989 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12767144 | 0.89 | ERN1 (0.80) | ERN1LCK | |
| SCHEMBL31060853 | 0.86 | ERN1 (1.00) | ERN1CA12CA1CA2CA9 | |
| SCHEMBL12767127 | 0.86 | ERN1 (1.00) | ERN1CA12CA1CA2CA9 | |
| SCHEMBL18904700 | 0.85 | ERN1 (0.56) | ERN1LCKCA12CA1CA2 | |
| SCHEMBL19967995 | 0.84 | ERN1 (0.69) | ERN1LCK | |
| SCHEMBL6288703 | 0.84 | ERN1 (0.55) | ERN1LCKCA12CA1CA2 | |
| SCHEMBL22750623 | 0.83 | ERN1 (0.62) | ERN1ALDH1A1MAPTHPGD | |
| SCHEMBL11660803 | 0.82 | ERN1 (0.58) | ERN1 | |
| SCHEMBL7590492 | 0.81 | LCK (1.00) | ERN1LCKCA12CA1CA2 | |
| SCHEMBL7214398 | 0.81 | ERN1 (0.78) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022716-A1 | POLYMERIZABLE COMPOUND AND OPTICAL ISOMER | DIC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
| US-20180022716-A1 | POLYMERIZABLE COMPOUND AND OPTICAL ISOMER | DIC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
| US-20170152206-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152206-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-06-01 | — | — | US | disclosed |
| EP-3150589-A1 | IRE-1A INHIBITORS | MannKind Corporation (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2155643-B1 | IRE-1A INHIBITORS | MANNKIND CORP (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2532643-A1 | IRE-1A Inhibitors | MannKind Corporation (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-2520561-A1 | IRE-1A Inhibitors | MannKind Corporation (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20110065162-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2011-03-17 | — | — | US | disclosed |
| US-7858666-B2 | inositol requiring enzyme 1 (IRE-1 alpha) inhibitors such as 2-hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde, relieve protein folding stress by enhancing molecular chaperone activity and protects cells from stress induced apoptosis; autoimmune diseases; anticancer; viricides | MANNKIND CORPORATION (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090186893-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2009-07-23 | — | — | US | disclosed |
| US-4150046-A | ORGANIC PIGMENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-04-17 | — | — | US | disclosed |
| US-4113759-A | PIGMENTS FOR PAINTS, LACQUERS, INKS, PLASTICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152206-A1 | IRE-1alpha INHIBITORS | XBP1, DDIT3, ERN1 | ERN1 3/4885LCK 4310/4885CA12 4808/4885 |
| US-20180022716-A1 | POLYMERIZABLE COMPOUND AND OPTICAL ISOMER | SMC4, MAP1LC3C, ZW10 | ERN1 2084/4885LCK 4626/4885CA12 2114/4885 |
| US-20090186893-A1 | IRE-1alpha INHIBITORS | XBP1, DDIT3, ERN1 | ERN1 3/4885LCK 4310/4885CA12 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.